Specifically, Min et al. [49] have demonstrated dysregulated cholesterol metabolism in NAFLD, which may contribute to disease severity through activation of SREBP2 and 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR). The gene discussed is SREBF2; the disease is metabolic dysfunction-associated steatotic liver disease.